International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3, Supplement , Pages S20-S27, 1 March 2010

Radiation Dose–Volume Effects in the Brain

  • Yaacov Richard Lawrence, M.R.C.P.

      Affiliations

    • Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA
    • Corresponding Author InformationReprint requests to: Yaacov Richard Lawrence, M.R.C.P., Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Bodine Cancer Center, 111 S. 11th St., Philadelphia, PA 19107. Tel: (215) 955-6700; Fax: (215) 955-0412
  • ,
  • X. Allen Li, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI
  • ,
  • Issam el Naqa, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO
  • ,
  • Carol A. Hahn, M.D.

      Affiliations

    • Department of Radiation Oncology, Duke University Medical Center, Durham, NC
  • ,
  • Lawrence B. Marks, M.D.

      Affiliations

    • Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC
  • ,
  • Thomas E. Merchant, D.O. Ph.D.

      Affiliations

    • Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN
  • ,
  • Adam P. Dicker, M.D. Ph.D.

      Affiliations

    • Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA

Received 26 November 2008; received in revised form 24 February 2009; accepted 27 February 2009.

We have reviewed the published data regarding radiotherapy (RT)-induced brain injury. Radiation necrosis appears a median of 1–2 years after RT; however, cognitive decline develops over many years. The incidence and severity is dose and volume dependent and can also be increased by chemotherapy, age, diabetes, and spatial factors. For fractionated RT with a fraction size of <2.5 Gy, an incidence of radiation necrosis of 5% and 10% is predicted to occur at a biologically effective dose of 120 Gy (range, 100–140) and 150 Gy (range, 140–170), respectively. For twice-daily fractionation, a steep increase in toxicity appears to occur when the biologically effective dose is >80 Gy. For large fraction sizes (≥2.5 Gy), the incidence and severity of toxicity is unpredictable. For single fraction radiosurgery, a clear correlation has been demonstrated between the target size and the risk of adverse events. Substantial variation among different centers' reported outcomes have prevented us from making toxicity–risk predictions. Cognitive dysfunction in children is largely seen for whole brain doses of ≥18 Gy. No substantial evidence has shown that RT induces irreversible cognitive decline in adults within 4 years of RT.

Radiotherapy, stereotactic radiosurgery, brain, tolerance, side effects

 

 Y. R. Lawrence is supported by The ASCO Cancer Foundation Young Investigator Award. Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the American Society of Clinical Oncology or The ASCO Cancer Foundation. L. B. Marks is supported by NIH R01 69579 and the Lance Armstrong Foundation.

 A. P. Dicker is supported by National Institutes of Health Grant CA10663, Tobacco Research Settlement Fund (State of Pennsylvania), and the Christine Baxter Fund.

 Conflict of interest: none.

PII: S0360-3016(09)03287-8

doi:10.1016/j.ijrobp.2009.02.091

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3, Supplement , Pages S20-S27, 1 March 2010